Holen Sie sich die Stockscreener-App
0.8601
13.99%
-0.1399
Lantern Pharma Inc Aktie (LTRN) Neueste Nachrichten
Lantern Pharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Lantern Pharma (NASDAQ: LTRN) Closes $4 Million Registered Direct Offering - The Globe and Mail
Lantern Pharma Inc. (LTRN) stock price, news, quote and history - Yahoo Finance UK
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering - biospace.com
Lantern Pharma closes $4 million stock offering By Investing.com - Investing.com South Africa
Lantern Pharma Raises $4.0 Million in Registered Direct; Issues Warrants, Engages Rodman & Renshaw - TradingView
Form 424B5 Lantern Pharma Inc For: 30 September - Investing.com India
Lantern Pharma Inc. (LTRN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering - biospace.com
Lantern Pharma raises $4M in registered direct offering - Investing.com
Lantern Pharma announces up to $8M registered direct offering - TradingView
Form 8K Lantern Pharma Inc For: 24 September By Investing.com - Investing.com Nigeria
Lantern Pharma hosts webinar on Open‑Medicine AI multi-agentic drug development platform - TradingView
Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic DevelopmentSlideshow (NASDAQ:LTRN) 2026-09-24 - Seeking Alpha
Lantern Pharma (NASDAQ: LTRN) Receives USPTO Notice of Allowance for LP-284 Blood Cancer Treatment Patent - The Globe and Mail
LTRN: Open Medicine AI expands its platform, targeting new diseases and broader adoption in drug development - TradingView
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET - BioSpace
Lantern Pharma Showcases Open-Medicine AI Growth Strategy - TipRanks
Form 8K Lantern Pharma Inc For: 23 September By Investing.com - Investing.com Nigeria
Lantern Pharma to present Open-Medicine AI roadmap, demo, commercial model in live webinar - TradingView
Lantern Pharma receives patent allowance for LP-284 cancer drug By Investing.com - Investing.com South Africa
Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas - biospace.com
Lantern Pharma (LTRN) Secures Patent Allowance for Blood Cancer Treatment, Faces Valuation Challenges - GuruFocus
Lantern Pharma secures USPTO notice of allowance for LP-284 patent - TipRanks
Lantern Pharma receives patent allowance for LP-284 cancer drug - Investing.com
Lantern Pharma to host webinar on Open-Medicine AI - TipRanks
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global - Eagle-Tribune
Lantern Pharma Inc (NASDAQ: LTRN) Share Price, LTRN Stock News, LTRN Share Price & Updates - kalkine.ca
Lantern Pharma Q2 2026 Earnings Call: Complete Transcript - Benzinga
Lantern Pharma to Present Open-Medicine AI, a Multi-Agentic Platform for End-to-End Therapeutic Development, Business Model, Roadmap, and Value Proposition on September 23 - marketscreener.com
LTRN News | LANTERN PHARMA INC (NASDAQ:LTRN) - ChartMill
Lantern Pharma (NASDAQ: LTRN) to Host Webinar on Open-Medicine AI Platform, Business Model and Development Roadmap - Barchart.com
Lantern Pharma (LTRN) to Host Webinar Highlighting AI-Driven The - GuruFocus
Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23 - Yahoo Finance
Lantern Pharma Share PriceLTRN, RNS News, Articles, Quotes, & Charts (NASDAQ:LTRN) - Proactive financial news
Why Did LTRN Stock Surge 18% In Pre-Market Today? - Stocktwits
New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST) - guardonline.com
Lantern Pharma Inc. (LTRN) Stock Price & News - Syfe
Lantern Pharma Earnings Call: AI Spinout, Trial Momentum - TipRanks
Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript - AOL.com
Here's Why We're A Bit Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation - Sahm
Lantern Pharma Inc (LTRN) (Q2 2026) Earnings Call Highlights: AI - GuruFocus
Lantern Pharma Inc (LTRN) (Q2 2026) Earnings Call Highlights: AI-Driven Pipeline Advances Amid ... - Yahoo Finance
Lantern Pharma Inc (LTRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lantern Pharma Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Lantern Pharma Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LTRN) 2026-08-17 - Seeking Alpha
Lantern Pharma (LTRN) Slides 2.26% as Biotech Stock Approaches Critical $2.46 SupportKey Reversal Day - vinanet.vn
Lantern Pharma (LTRN) Updates Trial Design Amid Cash Raise; Mark - GuruFocus
Lantern Pharma (LTRN) Edges Up 0.76% to $2.65: Rangebound Trading Between Support and ResistanceBull Pennant - vinanet.vn
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):